Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI116497

The serology of chronic hepatitis B infection revisited.

T Maruyama, A McLachlan, S Iino, K Koike, K Kurokawa, and D R Milich

Department of Molecular Biology, Scripps Research Institute, La Jolla, California 92037.

Find articles by Maruyama, T. in: PubMed | Google Scholar

Department of Molecular Biology, Scripps Research Institute, La Jolla, California 92037.

Find articles by McLachlan, A. in: PubMed | Google Scholar

Department of Molecular Biology, Scripps Research Institute, La Jolla, California 92037.

Find articles by Iino, S. in: PubMed | Google Scholar

Department of Molecular Biology, Scripps Research Institute, La Jolla, California 92037.

Find articles by Koike, K. in: PubMed | Google Scholar

Department of Molecular Biology, Scripps Research Institute, La Jolla, California 92037.

Find articles by Kurokawa, K. in: PubMed | Google Scholar

Department of Molecular Biology, Scripps Research Institute, La Jolla, California 92037.

Find articles by Milich, D. in: PubMed | Google Scholar

Published June 1, 1993 - More info

Published in Volume 91, Issue 6 on June 1, 1993
J Clin Invest. 1993;91(6):2586–2595. https://doi.org/10.1172/JCI116497.
© 1993 The American Society for Clinical Investigation
Published June 1, 1993 - Version history
View PDF
Abstract

The serology of chronic hepatitis B infection has been established through the use of commercial immunoassays to measure the structural antigens of the hepatitis B virus and their respective antibodies in serum. However, the commercial assays have not been designed to detect serum antibodies in the presence of an excess of circulating antigens. A series of serum samples from 200 HBeAg-positive, chronically infected hepatitis B patients with varying degrees of liver disease were analyzed using novel immunoassays designed to detect antibodies in the presence of circulating viral antigens. All patients, regardless of their liver disease, were seronegative for antibodies specific for the envelope antigens or the secreted nucleoprotein antigen (HBeAg) when the commercial assays were used. In contrast, virtually all chronically infected patients with liver disease and approximately 50% of patients without liver disease demonstrated anti-HBe and anti-envelope antibodies when sera were tested in the more sensitive immunoassays. Furthermore, asymptomatic patients could be serologically distinguished from symptomatic patients based on antibody fine specificity, titer, and IgG subclass. This study revealed that the majority of chronically infected hepatitis B patients produce a variety of antibodies for many years, and are not immunologically unresponsive, as suggested by the current assays.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2586
page 2586
icon of scanned page 2587
page 2587
icon of scanned page 2588
page 2588
icon of scanned page 2589
page 2589
icon of scanned page 2590
page 2590
icon of scanned page 2591
page 2591
icon of scanned page 2592
page 2592
icon of scanned page 2593
page 2593
icon of scanned page 2594
page 2594
icon of scanned page 2595
page 2595
Version history
  • Version 1 (June 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts